GLP-1 receptor agonists show experimental evidence of reducing ferroptosis and pyroptosis—two forms of cell death implicated in diabetic kidney disease and metabolic liver disease—with effects comparable to dedicated ferroptosis inhibitors.
Comparable to ferrostatin-1GLP-1 drugs reduced ferroptosis markers as effectively as a dedicated ferroptosis inhibitor in experimental diabetes models
What the researchers found
GLP-1RAs reduced ferroptosis markers (decreased ACSL4, increased protective factors) comparably to ferrostatin-1 and suppressed pyroptosis markers (caspase-1, GSDMD, IL-1β, NLRP3) in experimental models of diabetic kidney disease and metabolic liver disease, with additional anti-inflammatory, anti-fibrotic, and antioxidant effects.
Why it matters
Diabetic kidney disease and metabolic liver disease are major complications of diabetes with limited treatment options. If GLP-1 drugs can protect organ tissue by preventing these specific forms of cell death, it adds a powerful mechanistic rationale for their use beyond blood sugar and weight control.
The numbers in context
GLP-1RAs reduced ACSL4 (ferroptosis marker), increased protective factors, and decreased caspase-1, GSDMD, and IL-1-beta (pyroptosis markers) in experimental models of diabetic kidney disease and MASLD.
How the study worked
Narrative review synthesizing experimental (in vitro and animal model) evidence on GLP-1RA effects on ferroptosis and pyroptosis in diabetes and diabetic complications.
Who was studied
Preclinical models of diabetes, diabetic kidney disease, and MASLD
What this study cannot tell us
All evidence is from experimental models (cell cultures and animals). No clinical trial data exists for these specific mechanisms. The review is narrative, not systematic. Translation from experimental findings to human clinical benefit is uncertain.
How to read the evidence
Narrative review of preclinical evidence. Mechanistic findings are consistent and biologically plausible but entirely based on experimental models without clinical validation.
When this study was published
Published in 2025; reviews the latest experimental evidence on GLP-1RA pleiotropic effects.
The bigger picture
This review expands the understood benefits of GLP-1 drugs from glucose control and weight loss into fundamental cell biology—preventing specific modes of cell death that damage kidneys and liver in diabetes. It suggests GLP-1 agonists may have organ-protective effects that go far beyond their metabolic actions.
Questions still open
- Will clinical trials confirm that GLP-1 drugs reduce ferroptosis and pyroptosis markers in diabetic patients?
- Could combining GLP-1 agonists with dedicated ferroptosis inhibitors provide additive kidney protection?
- Are these cell-death-reducing effects specific to GLP-1RAs or shared by other diabetes medications like SGLT2 inhibitors?
Common questions
What are ferroptosis and pyroptosis?
Does this mean GLP-1 drugs protect kidneys and liver?
Read the original research
Ferroptosis and pyroptosis in diabetes mellitus: emerging therapeutic potential of GLP-1 receptor agonists.
Frontiers in clinical diabetes and healthcare, 6, 1657710
Citation
Panou, Theodoros; Gouveri, Evanthia; Rizzo, Manfredi; Popovic, Djordje S; Papanas, Nikolaos. (2025). Ferroptosis and pyroptosis in diabetes mellitus: emerging therapeutic potential of GLP-1 receptor agonists.. Frontiers in clinical diabetes and healthcare, 6, 1657710. https://doi.org/10.3389/fcdhc.2025.1657710